Rockefeller Capital Management L.P. Has $1.61 Million Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Rockefeller Capital Management L.P. boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 81.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 137,838 shares of the company's stock after buying an additional 61,800 shares during the period. Rockefeller Capital Management L.P. owned about 0.14% of Intellia Therapeutics worth $1,607,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Regeneron Pharmaceuticals Inc. acquired a new position in Intellia Therapeutics in the 4th quarter worth approximately $43,177,000. Contrarius Group Holdings Ltd acquired a new position in Intellia Therapeutics during the fourth quarter valued at $11,798,000. Trexquant Investment LP purchased a new position in Intellia Therapeutics during the 4th quarter valued at about $7,785,000. Vanguard Group Inc. increased its holdings in shares of Intellia Therapeutics by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock valued at $118,816,000 after purchasing an additional 562,249 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Intellia Therapeutics in the fourth quarter worth approximately $4,793,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Trading Down 0.7 %

NASDAQ:NTLA traded down $0.06 during mid-day trading on Friday, hitting $8.13. The company's stock had a trading volume of 553,058 shares, compared to its average volume of 2,371,431. The company has a market capitalization of $841.08 million, a price-to-earnings ratio of -1.49 and a beta of 2.23. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.18. The stock has a fifty day moving average of $8.73 and a 200-day moving average of $11.92.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on NTLA shares. Wells Fargo & Company dropped their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Citigroup lifted their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the company a "neutral" rating in a research report on Friday, February 28th. The Goldman Sachs Group reaffirmed a "sell" rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 28th. Truist Financial lowered their price target on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Finally, Chardan Capital reduced their target price on shares of Intellia Therapeutics from $91.00 to $68.00 and set a "buy" rating for the company in a research note on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $36.68.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.